Dexmedetomidine does not attenuate increases in excitatory amino acids after transient global ischemia in the rabbit

Journal of Neurosurgical Anesthesiology

Volumn 8, Issue 3, 1996, Pages 230-235

  Kim, Hae Kyu ^a   Zornow, Mark H ^a   Strnat, Martin A P ^a   Maze, Mervyn ^b,c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Dexmedetomidine; Excitatory amino acids; Global cerebral ischemia; Microdialysis; Rabbit; Adrenergic agonist

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; DEXMEDETOMIDINE; EXCITATORY AMINO ACID; GLUTAMIC ACID; GLYCINE;

ANESTHESIA INDUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; DIALYSATE; HYPOTENSION; MICRODIALYSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION;

EID: 0012113312     PISSN: 08984921     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008506-199607000-00008     Document Type: Article

References (40)

1. Benveniste H, Drejer J, Schousboe A, et al. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984;43: 1369-74
2. Benveniste H. The excitotoxin hypothesis in relation to cerebral ischemia. Cerebrovasc Brain Metab Rev 1991;3: 213-45.
3. Choi DW, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci 1987;7: 357-68.
4. Benveniste H, Jorgensen MB, Sandberg M, et al. Ischemic damage in hippocampal CA1 is dependent on glutamate release and intact innervation from CA3. J Cereb Blood Flow Metab 1989;9:629-39.
5. Wieloch T, Lindvall O, Blomqvist P, et al. Evidence for amelioration of ischaemic neuronal damage in the hippocampal formation by lesions of the perforant path. Neurol Res 1985;7:24-6.
6. Dalkara T, Erdemli G, Barun S, et al. Glycine is required for NMDA receptor activation: electrophysiological evidence from intact rat hippocampus. Brain Res 1992;576:197-202.
7. Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 1988;241:835-7.
8. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987;325: 529-31.
9. Thomson AM, Walker VE, Flynn DM. Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices. Nature 1989;338:422-4.
10. Larson AA, Beitz AJ. Glycine potentiates strychnine-induced convulsions: role of NMDA receptors. J Neurosci 1988;8:3822-6.
11. Baker AJ, Zornow MH, Scheller MS, et al. Changes in extracellular concentrations of glutamate, aspartate, glycine, dopamine, serotonin, and dopamine metabolites after transient global ischemia in the rabbit brain. J Neurochem 1991; 57:1370-9.
12. Unnerstall JR, Kopajtic TA, Kuhar MJ. Distribution of alpha-2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res 1984;319:69-101.
13. Kuhar MJ, Unnerstall JR. Mapping receptors for alpha-2 agonists in the central nervous system. J Cardiovasc Pharmacol 1984;6:S536-42.
14. Maze M, Segal IS, Bloor BC. Clonidine and other alpha-2 adrenergic agonists: strategies for the rational use of these novel anesthetic agents. J Clin Anesth 1988;1:146-57.
15. Vickery RG, Sheridan BC, Segal IS, et al. Anesthetic and hemodynamic effects of the stereoisomers of medetomidine, an alpha-2 adrenergic agonist, in halothane-anesthetized dogs. Anesth Analg 1988;67:611-15.
16. Segal IS, Vickery RG, Walton JK, et al. Dexmedetomidine diminishes halothane anesthetic requirements in rats through a postsynaptic alpha-2 adrenergic receptor. Anesthesiology 1988;69:818-23.
17. Scheinin M, Kallio A, Koulu M, et al. Sedative and cardiovascular effects of medetomidine, a novel selective alpha-2 adrenoceptor agonist, in healthy volunteers. Br J Clin Pharmacol 1987;24:443-51.
18. Hoffman WE, Kochs E, Werner C, et al. Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha 2-adrenergic antagonist atipamezole. Anesthesiology 1991;75:328-32.
19. Maier C, Steinberg GK, Sun GH, et al. Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 1993;79: 306-12.
20. Matsumoto M, Zornow MH, Rabin BC, et al. The alpha-2 adrenergic agonist, dexmedetomidine, selectively attenuates ischemia-induced increases in striatal norepinephrine concentrations. Brain Res 1993;627:325-9.
21. Baker AJ, Zornow MH, Grafe MR, et al. Hypothermia prevents ischemia-induced increases in hippocampal glycine concentrations in rabbits. Stroke 1991;22:666-73.
22. Globus MY, Busto R, Dietrich WD, et al. Direct evidence for acute and massive norepinephrine release in the hippocampus during transient ischemia. J Cereb Blood Flow Metab 1989;9:892-6.
23. Bhardwaj A, Brannan T, Martinez-Tica J, et al. Ischemia in the dorsal hippocampus is associated with acute extracellular release of dopamine and norepinephrine. J Neural Transm 1990;80:195-201.
24. Madison DV, Nicoll RA. Actions of noradrenaline recorded intracellularly in rat hippocampal CA1 pyramidal neurones, in vitro. J Physiol 1986;372:221-44.
25. Stein SC, Cracco RQ. Cortical injury without ischemia produced by topical monoamines. Stroke 1982;13:74-83.
26. Werner C, Hoffman WE, Thomas C, et al. Ganglionic blockade improves neurologic outcome from incomplete ischemia in rats: partial reversal by exogenous catecholamines. Anesthesiology 1990;73:923-9.
27. Blomqvist P, Lindvall O, Wieloch T. Lesions of the locus coeruleus system aggravate ischemic damage in the rat brain. Neurosci Lett 1985;58:353-8.
28. Koide T, Wieloch TW, Siesjo BK. Circulating catecholamines modulate ischemic brain damage. J Cereb Blood Flow Metab 1986;6:559-65.
29. Cheng MA, Hoffman WE, Miletich DJ, et al. Clonidine improves neurologic outcome following incomplete ischemia in rats. Anesth Analg 1991;72:S39.
30. Scheinin H, Virtanen R, Scheinin M. Alpha-2 adrenoreceptor antagonists decrease free 3-methoxy-4-hydroxyphenylglycol in rat cerebrospinal fluid. Eur J Pharmacol 1986;123: 115-21.
31. Savola JM, Ruskoaho H, Puurunen J, et al. Evidence of medetomidine as a selective and potent agonist at alpha-2 adrenoreceptors. J Auton Pharmacol 1986;6:275-84.
32. Miyazaki M, Nazarali AJ, Boisvert DP, et al. Inhibition of ischemia-induced brain catecholamine alterations by clonidine. Brain Res Bull 1989;22:207-11.
33. Zornow MH, Fleischer JE, Scheller MS, et al. Dexmedetomidine, an alpha 2-adrenergic agonist, decreases cerebral blood flow in the isoflurane-anesthetized dog. Anesth Analg 1990;70:624-30.
34. Zornow MH, Maze M, Dyck JB, et al. Dexmedetomidine decreases cerebral blood flow velocity in humans. J Cereb Blood Flow Metab 1993;13:350-3.
35. Dolphin AC. Noradrenergic modulation of glutamate release in the cerebellum. Brain Res 1982;252:111-16.
36. Mori-Okamoto J, Namii Y, Tatsuno J. Subtypes of adrenergic receptors and intracellular mechanisms involved in modulatory effects of noradrenaline on glutamate. Brain Res 1991;539:67-75.
37. Matsumoto M, Zornow M, Rabin B, et al. The alpha-2 adrenergic agonist, dexmedetomidine, selectively attenuates ischemia-induced increases in striatal norepinephrine concentrations. Brain Res 1993;627:325-9.
38. Crowder JM, Bradford HF. Inhibitory effects of noradrenaline and dopamine on calcium influx and neurotransmitter glutamate release in mammalian brain slices. Eur J Pharmacol 1987;143:343-52.
39. Kamisaki Y, Hamahashi T, Okada CM, et al. Clonidine inhibition of potassium-evoked release of glutamate and aspartate from rat cortical synaptosomes. Brain Res 1991;568: 193-8.
40. Crowder J, Bradford H. Inhibitory effects of noradrenaline and dopamine on calcium influx and neurotransmitter glutamate release in mammalian brain slices. Eur J Pharmacol 1987;143:343-52.